1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Summary of patient characteristics, treatment, and outcome
No. of Patients (N = 13)
Male sex 11 (84.6%)
Age (mean ± SD) (yr) 56 ± 6.2
Pretreatment NIHSS (mean ± SD) 26 ± 4
Symptom-to-door time (mean ± SD) (min) 587 ± 341
Needle-to-recanalization (mean ± SD) (min) 93 ± 28
Door-to-reperfusion (mean ± SD) (min) 301 ± 117
Underlying site of stenosis 
    BA 10 (76.9%)
    V4 3 (13%)
Endovascular treatment for the stenosis 
    PTA alone 3 (23.1%)
    Apollo stent 3 (23.1%)
    Wingspan stent 7 (53.8%)
Glycoprotein IIb/IIIa inhibitor 6 (46.2%)
Pre-PTA/stenting stenosis (mean ± SD) 91.5 ± 2.4%
Post-PTA/stenting stenosis (mean ± SD) 24.6 ± 12.6%
Pre-PTA/stenting TICI (post-mechanical thrombectomy) 
    0 2 (5.4%)
    1 7 (53.8%)
    2a 4 (30.8%)
Post-PTA/stenting TICI 
    2b 3 (23.1%)
    3 10 (76.9%)
Distal embolization to PCA/cerebellar arteries 3 (23.1%)
Outcome 
    NIHSS score on discharge for surviving patients (mean ± SD) 12 ± 6
    % of patients with NIHSS ≥10-point improvement 10 (79.9%)
    Mortality on discharge 2 (15.3%)
    mRS at 90 days 
        mRS 0–2 6 (46.2%)
        mRS 0–3 9 (69.2%)
    Ischemic events at 90-day follow-up 0 (0%)
Note:—BA indicates basilar artery; PCA, posterior cerebral artery; V4, vertebral artery V4 segment.